CA3202770A1 - Macrocycles and their use - Google Patents
Macrocycles and their useInfo
- Publication number
- CA3202770A1 CA3202770A1 CA3202770A CA3202770A CA3202770A1 CA 3202770 A1 CA3202770 A1 CA 3202770A1 CA 3202770 A CA3202770 A CA 3202770A CA 3202770 A CA3202770 A CA 3202770A CA 3202770 A1 CA3202770 A1 CA 3202770A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- nrarb
- alkylene
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126722P | 2020-12-17 | 2020-12-17 | |
| US63/126,722 | 2020-12-17 | ||
| US202163279850P | 2021-11-16 | 2021-11-16 | |
| US63/279,850 | 2021-11-16 | ||
| US202163284789P | 2021-12-01 | 2021-12-01 | |
| US63/284,789 | 2021-12-01 | ||
| US202163289014P | 2021-12-13 | 2021-12-13 | |
| US63/289,014 | 2021-12-13 | ||
| PCT/US2021/063721 WO2022133037A1 (en) | 2020-12-17 | 2021-12-16 | Macrocycles and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202770A1 true CA3202770A1 (en) | 2022-06-23 |
Family
ID=82058646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202770A Pending CA3202770A1 (en) | 2020-12-17 | 2021-12-16 | Macrocycles and their use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182487A1 (https=) |
| EP (1) | EP4262796A4 (https=) |
| JP (1) | JP2023553835A (https=) |
| KR (1) | KR20230121773A (https=) |
| AU (1) | AU2021401741A1 (https=) |
| CA (1) | CA3202770A1 (https=) |
| IL (1) | IL303419A (https=) |
| MX (1) | MX2023007162A (https=) |
| PY (1) | PY21110949A (https=) |
| UY (1) | UY39574A (https=) |
| WO (1) | WO2022133037A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023283476A1 (en) * | 2022-06-08 | 2024-11-14 | Blossomhill Therapeutics, Inc. | Indazole macrocycles and their use |
| CA3258157A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole-Containing Macrocycles and Their Use |
| JP2025524038A (ja) * | 2022-07-27 | 2025-07-25 | 上海和誉生物医薬科技有限公司 | 大環状ｅｇｆｒ阻害剤、その製造方法及び薬学における応用 |
| EP4655304A1 (en) * | 2023-02-22 | 2025-12-03 | Yuhan Corporation | Macrocyclic aminopyridine compounds as egfr inhibitors |
| JP2026507654A (ja) * | 2023-02-22 | 2026-03-04 | ユーハン・コーポレイション | Ｅｇｆｒ阻害剤としての大環状アミノピリジン化合物 |
| KR20250142978A (ko) * | 2023-02-22 | 2025-09-30 | 주식회사유한양행 | Egfr 억제제로서의 마크로시클릭 아미노피리딘 화합물 |
| EP4688750A1 (en) | 2023-04-06 | 2026-02-11 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| AU2024266587A1 (en) * | 2023-05-02 | 2025-09-11 | Blossomhill Therapeutics, Inc. | Egfr inhibitors for treating disease |
| EP4731213A2 (en) * | 2023-06-23 | 2026-04-29 | Blossomhill Therapeutics, Inc. | Combination therapy involving macrocyclic indazole compounds |
| WO2025122911A1 (en) * | 2023-12-07 | 2025-06-12 | Blossomhill Therapeutics, Inc. | Indazole macrocycle polymorphs |
| WO2025122859A1 (en) * | 2023-12-08 | 2025-06-12 | Blossomhill Therapeutics, Inc. | Indazole-based macrocyclic compounds |
| WO2025199438A1 (en) * | 2024-03-22 | 2025-09-25 | Blossomhill Therapeutics, Inc. | 7-azaindazole macrocycles and their use |
| WO2025245175A1 (en) * | 2024-05-22 | 2025-11-27 | Ajax Therapeutics, Inc. | Macrocyclic heteroaromatic inhibitors of jak2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| DK2822953T5 (en) * | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
| CN111269245B (zh) * | 2018-12-04 | 2021-08-27 | 杭州百新生物医药科技有限公司 | 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途 |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
-
2021
- 2021-12-16 WO PCT/US2021/063721 patent/WO2022133037A1/en not_active Ceased
- 2021-12-16 US US18/257,166 patent/US20240182487A1/en active Pending
- 2021-12-16 AU AU2021401741A patent/AU2021401741A1/en active Pending
- 2021-12-16 KR KR1020237021826A patent/KR20230121773A/ko active Pending
- 2021-12-16 MX MX2023007162A patent/MX2023007162A/es unknown
- 2021-12-16 EP EP21907788.0A patent/EP4262796A4/en active Pending
- 2021-12-16 JP JP2023532465A patent/JP2023553835A/ja active Pending
- 2021-12-16 CA CA3202770A patent/CA3202770A1/en active Pending
- 2021-12-16 IL IL303419A patent/IL303419A/en unknown
- 2021-12-17 UY UY0001039574A patent/UY39574A/es unknown
- 2021-12-17 PY PY202121110949A patent/PY21110949A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230121773A (ko) | 2023-08-21 |
| IL303419A (en) | 2023-08-01 |
| AU2021401741A1 (en) | 2023-06-29 |
| US20240182487A1 (en) | 2024-06-06 |
| WO2022133037A1 (en) | 2022-06-23 |
| EP4262796A4 (en) | 2025-04-02 |
| JP2023553835A (ja) | 2023-12-26 |
| EP4262796A1 (en) | 2023-10-25 |
| MX2023007162A (es) | 2023-06-29 |
| PY21110949A (es) | 2023-08-07 |
| TW202241911A (zh) | 2022-11-01 |
| AU2021401741A9 (en) | 2024-09-19 |
| UY39574A (es) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3202770A1 (en) | Macrocycles and their use | |
| CA2936079C (en) | Diaryl macrocycles as modulators of protein kinases | |
| EP2456774B1 (en) | Fused aminodihydro-oxazine derivatives | |
| JP2022523981A (ja) | 抗癌剤として有用な縮合三環式化合物 | |
| JP7405468B2 (ja) | Ｂｒｄ４阻害活性を有する化合物、その調製方法および用途 | |
| JP7713619B2 (ja) | 大員環分子およびそれらの使用 | |
| WO2015095492A1 (en) | Tricyclic heterocycles as bet protein inhibitors | |
| CA3241069A1 (en) | Macrocyclic btk inhibitors | |
| KR20250004897A (ko) | 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 | |
| JP2025527170A (ja) | アミノヘテロアリールキナーゼ阻害剤 | |
| CA3258157A1 (en) | Indazole-Containing Macrocycles and Their Use | |
| CA3231988A1 (en) | Azaindazole macrocycle compound and use thereof | |
| IL324276A (en) | Egfr inhibitors for treating disease | |
| CN119894891A (zh) | 一种kras g12d抑制剂及其应用 | |
| CN116635076A (zh) | 大环化合物及其用途 | |
| CN121974931A (en) | Macrocyclic compounds and uses thereof | |
| WO2025194599A1 (en) | Heterocycle ulk1/2 inhibitors and methods of use thereof | |
| CN120590414A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| HK40094677A (zh) | 大环化合物及其用途 | |
| JP2024545511A (ja) | メニン－ｍｌｌ相互作用の阻害剤 | |
| HK1171742A (en) | Tricyclic pyrazol amine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251212 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260212 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260219 |